CN115948339A - 高通量气液交界法培养神经胶质瘤类器官的方法 - Google Patents
高通量气液交界法培养神经胶质瘤类器官的方法 Download PDFInfo
- Publication number
- CN115948339A CN115948339A CN202310092404.7A CN202310092404A CN115948339A CN 115948339 A CN115948339 A CN 115948339A CN 202310092404 A CN202310092404 A CN 202310092404A CN 115948339 A CN115948339 A CN 115948339A
- Authority
- CN
- China
- Prior art keywords
- culture
- groove
- organoid
- glioma
- matrigel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002220 organoid Anatomy 0.000 title claims abstract description 122
- 206010018338 Glioma Diseases 0.000 title claims abstract description 50
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 48
- 238000012258 culturing Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title abstract description 44
- 239000007788 liquid Substances 0.000 title abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 57
- 229940079593 drug Drugs 0.000 claims abstract description 53
- 238000012360 testing method Methods 0.000 claims abstract description 40
- 210000001519 tissue Anatomy 0.000 claims abstract description 40
- 230000035945 sensitivity Effects 0.000 claims abstract description 36
- 238000012136 culture method Methods 0.000 claims abstract description 21
- 108010082117 matrigel Proteins 0.000 claims description 51
- 239000000758 substrate Substances 0.000 claims description 34
- 238000004113 cell culture Methods 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 16
- 238000007711 solidification Methods 0.000 claims description 5
- 230000008023 solidification Effects 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108091016585 CD44 antigen Proteins 0.000 claims description 2
- 102000004266 Collagen Type IV Human genes 0.000 claims description 2
- 108010042086 Collagen Type IV Proteins 0.000 claims description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 2
- 108090000054 Syndecan-2 Proteins 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 108010008217 nidogen Proteins 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 238000011065 in-situ storage Methods 0.000 abstract description 5
- 238000011081 inoculation Methods 0.000 abstract description 4
- 230000009257 reactivity Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 48
- 239000000243 solution Substances 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 229940125644 antibody drug Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241001533159 Brucea javanica Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000010889 Rhus javanica Nutrition 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310092404.7A CN115948339A (zh) | 2023-01-18 | 2023-01-18 | 高通量气液交界法培养神经胶质瘤类器官的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310092404.7A CN115948339A (zh) | 2023-01-18 | 2023-01-18 | 高通量气液交界法培养神经胶质瘤类器官的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115948339A true CN115948339A (zh) | 2023-04-11 |
Family
ID=87297430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310092404.7A Pending CN115948339A (zh) | 2023-01-18 | 2023-01-18 | 高通量气液交界法培养神经胶质瘤类器官的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115948339A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117625541A (zh) * | 2024-01-26 | 2024-03-01 | 零壹人工智能科技研究院(南京)有限公司 | 一种脑胶质瘤类器官构建方法及药敏检测方法 |
-
2023
- 2023-01-18 CN CN202310092404.7A patent/CN115948339A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117625541A (zh) * | 2024-01-26 | 2024-03-01 | 零壹人工智能科技研究院(南京)有限公司 | 一种脑胶质瘤类器官构建方法及药敏检测方法 |
CN117625541B (zh) * | 2024-01-26 | 2024-04-02 | 零壹人工智能科技研究院(南京)有限公司 | 一种脑胶质瘤类器官构建方法及药敏检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3515600B1 (en) | Organoid arrays | |
JP7373872B2 (ja) | 初代乳房上皮細胞培養培地、培養方法、及びその使用 | |
CN108026499B (zh) | 用于繁殖微组织的装置 | |
US20230235283A1 (en) | Culture medium for esophageal squamous cell carcinoma epithelial cells, culture method, and application thereof | |
JP6849719B2 (ja) | オートメーション化された細胞培養システム及び方法 | |
Bray et al. | Addressing patient specificity in the engineering of tumor models | |
Clinton et al. | Initiation, expansion, and cryopreservation of human primary tissue‐derived normal and diseased organoids in embedded three‐dimensional culture | |
JPWO2018169007A1 (ja) | 腫瘍組織を用いた初代がん細胞の3次元培養 | |
US20160281061A1 (en) | Tissue array for cell spheroids and methods of use | |
KR20210108865A (ko) | 환자 맞춤형 약물 선택을 위한 정보 제공 방법 | |
CN115948339A (zh) | 高通量气液交界法培养神经胶质瘤类器官的方法 | |
Bregenzer et al. | Physiologic patient derived 3D spheroids for anti-neoplastic drug screening to target cancer stem cells | |
Horie et al. | Three-dimensional co-culture model for tumor-stromal interaction | |
Radajewska et al. | Three dimensional in vitro culture systems in anticancer drug discovery targeted on cancer stem cells | |
WO2023279455A1 (zh) | 一种用于肺癌上皮细胞的培养基、培养方法及其应用 | |
WO2006057444A1 (ja) | 細胞の分化度自動診断方法 | |
Nault et al. | Dissociated hippocampal cultures | |
KR20240029728A (ko) | 개인 맞춤형 약 및 약물 개발에 사용하기 위한 미세-유기구체 | |
US20240018452A1 (en) | Chip for integrated tumor cell behavior experiments | |
RU2819362C1 (ru) | Культуральная среда для первичных эпителиальных клеток молочной железы, способ их культивирования и их применение | |
WO2013142393A1 (en) | Method and apparatus for collecting, transporting and maintaining live tumor specimens ex vivo | |
CN216303865U (zh) | 生物培养芯片及其用于制备所述生物培养芯片的模板 | |
US20240026268A1 (en) | Microfluidic hanging drop culture device for culturing cell aggregate | |
US20230151325A1 (en) | Method for screening for target cells or cells, and biological culture chip | |
Aggarwal et al. | Establishment and Culture of Patient-Derived Breast Organoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240206 Address after: 102200 910, unit 1, building 1, yard 1, Longyu middle street, Huilongguan town, Changping District, Beijing Applicant after: Beijing sailada Biotechnology Co.,Ltd. Country or region after: China Address before: B1/F, Building 3, Comprehensive R&D Base, No. 9 Shengshengyuan Road, Changping District, Beijing, 102206 Applicant before: Zheng Lemin Country or region before: China Applicant before: Beijing sailada Biotechnology Co.,Ltd. |